NYU study finds the first genetic link between GLP-1 receptor activity and male pattern hair loss

Researchers at NYU Langone Health report the first genetic evidence tying GLP-1 receptor activity to male pattern hair loss. In a study published online September 3 in the Journal of Investigative Dermatology, men with genetically higher GLP-1 receptor activity had a 7 percent added risk of androgenetic alopecia, the inherited form of balding that follows a pattern along the top and front of the scalp ^[1][2].

The team did not track people who take semaglutide (Ozempic, Wegovy) or tirzepatide (Zepbound). Instead, they focused on the GLP1R gene, which governs how many GLP-1 receptor proteins the body makes, and used natural variation in that gene as a stand-in for GLP-1 agonist activity — more GLP1R activity means more GLP-1 receptor proteins ^[1][2]. They then checked whether those gene variants showed up more often in men who have androgenetic alopecia. They did ^[1][2].

What the numbers show

The analysis drew on large, publicly available genetic databases: the eQTLGen database of 31,684 mostly White men and women, and a Complex Traits Genetics group database of 205,327 mostly White men ^[1][2].

The researchers then tried to rule out other explanations. They adjusted for hypertension, which is thought to reduce blood flow to the scalp and harm follicle growth; the 7 percent added risk did not change ^[1][2]. They also checked insulin resistance, a driver of type 2 diabetes, and lowered testosterone levels. The 7 percent figure held ^[1][2].

"Our study provides the first genetic link between GLP-1 use and an increased risk of male-pattern hair loss from androgenetic alopecia, an association long suspected but until now not shown scientifically," said senior investigator Lynn Petukhova, PhD, an assistant professor in the Ronald O. Perelman Department of Dermatology and the Department of Population Health at NYU Grossman School of Medicine ^[1][2].

Up to now, hair shedding reported by GLP-1 users — both men and women — has generally been attributed to rapid weight loss rather than the drugs themselves, and many users find that hair growth resumes several months after their weight stabilizes ^[1][2].

Important limits

The study cannot explain how GLP-1 activity affects hair follicles. Petukhova said further research is needed to understand the biological mechanisms ^[1][2]. It also covered only men: male hair loss conditions are well studied while hair loss in women is not, so the researchers could analyze a causal link only in men ^[1][2]. Petukhova said she plans to investigate whether the findings apply to women ^[1][2].

The databases were described as mostly White participants, so it is not known from these sources whether the same pattern appears in other groups ^[1][2]. And because the work used gene variants as a proxy rather than prescription or dosing records, the sources do not report any hair-loss rate measured directly in people taking these medicines.

Several co-investigators disclosed industry ties. Drs. Jerry Shapiro and Kristen Lo Sicco have served as study investigators for hair loss drugs and devices made by Pfizer and Regen Labs, and Dr. Lo Sicco is a paid consultant for Pfizer, Lilly, Ro, Priovant, Veradermics, and Aquis ^[1][2]. The work was funded by National Institutes of Health grants R01AR080796 and K01AR075111 ^[1][2].

Why it matters for patients

Hair thinning is one of the more commonly discussed complaints among GLP-1 users, and it has largely been chalked up to fast weight loss. This study suggests the receptor itself may play some role, at least in men genetically predisposed to pattern baldness ^[1][2]. A 7 percent relative increase is small compared with the baseline: androgenetic alopecia is estimated to affect half of White American males over age 50, and nearly the same share of White American females over 50, mostly after menopause ^[1][2].

The researchers raised two possible future uses. "Some men, and possibly women too, could be screened and benchmarked for their risk of hair loss before being prescribed GLP-1 medications," Petukhova said, adding that the findings could eventually lead to combination treatments to prevent hair loss, "such as minoxidil or some other drug" ^[1][2]. Both ideas depend on future experiments that have not been done.

Context on use

An estimated 12 percent of Americans have used GLP-1 drugs solely for weight loss, including one-fifth of women ages 50 to 64, according to surveys cited by NYU Langone ^[1][2]. The release states that prescriptions have more than tripled since the FDA approved the first GLP-1 drug, which it identifies as Ozempic in 2020 ^[1][2].

No timeline was given for the follow-up studies in women or for mechanism research.